TY  - JOUR
AU  - Betge, Johannes
AU  - Barat, Ana
AU  - Murphy, Verena
AU  - Hielscher, Thomas
AU  - Van Grieken, Nicole C
AU  - Belle, Sebastian
AU  - Zhan, Tianzuo
AU  - Härtel, Nicolai
AU  - Kripp, Melanie
AU  - Bacon, Orna
AU  - Cordes, Martijn
AU  - Kay, Elaine W
AU  - Verheul, Henk M W
AU  - Neerincx, Maarten
AU  - Hennessy, Bryan
AU  - Hofheinz, Ralf D
AU  - Gaiser, Timo
AU  - Ylstra, Bauke
AU  - Prehn, Jochen H M
AU  - Lambrechts, Diether
AU  - Byrne, Annette T
AU  - Ebert, Matthias P
AU  - Schulte, Nadine
TI  - Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
JO  - Digestion
VL  - 94
IS  - 3
SN  - 1421-9867
CY  - Basel
PB  - Karger
M1  - DKFZ-2017-01635
SP  - 129 - 137
PY  - 2016
AB  - This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
KW  - Angiogenesis Inhibitors (NLM Chemicals)
KW  - Pyrimidines (NLM Chemicals)
KW  - Bevacizumab (NLM Chemicals)
KW  - 5-fluoropyrimidine (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27756074
DO  - DOI:10.1159/000449412
UR  - https://inrepo02.dkfz.de/record/125509
ER  -